The FDA requests that if you have had any experience with the cannabidiol compound found in cannabis, abbreviated CBD, to leave a comment on the regulations.gov website. CBD is a non-euphoric compound found in marijuana and is given the most credit for having the medicinal properties of marijuana.
The United States federal government has very strict policies regarding marijuana and even lists it as a Schedule 1 drug, which means that it is highly addictive and has no medical value. There is a huge movement occurring in the country to break the stigmas surrounding the drug and a push for it become legal throughout the country. Have you tried CBD and seen that it has helped provide you with any relief?
The United Nations is trying to figure out how to categorize cannabidiol (CBD), a non-psychoactive and medically beneficial cannabinoid contained in cannabis. And UN officials, through the US Food and Drug Administration (FDA), are asking for your help.
FDA officials put out a call for comments in this morning’s Federal Register, seeking information about CBD and how the UN’s World Health Organization (WHO) should designate it under the 1971 Convention on Psychotropic Substances. In doing so, the FDA acknowledged the ‘beneficial’ effects CBD has shown in patients with neurological disorders.
All those who have information on, or experience with, the use of CBD as a healing substance are encouraged to comment at this federal website. Sept. 13 is the deadline for public comment, and no input will be considered after that date.
CBD is one of 17 substances currently under scheduling review by the WHO. This process affects only the WHO and the United Nations. It does not directly deal with the status of CBD under the federal Controlled Substances Act—but it could have an indirect effect by influencing the outcome of the conflict over the federal categorization of cannabidiol.
FDA Deputy Commissioner Anna K. Abram, who sent out the notice this morning, acknowledged that “CBD has been shown to be beneficial in experimental models of several neurological disorders, including those of seizure and epilepsy.”
That puts the FDA at odds with the US Drug Enforcement Administration (DEA), which late last year attempted to declare CBD a Schedule I substance. Schedule I drugs, by definition, have “no currently accepted medical use in treatment in the United States.”
The other drugs under consideration by the UN include six types of the synthetic opioid fentanyl, five synthetic cannabinoid agonists (of the K2 and Spice type), and the psychoactive muscle relaxant ketamine.
The UN has struggled with ketamine for years, having previously reviewed its status in 2006, 2012, and 2014. In 2015, a UN agency decided to postpone a proposal to place ketamine in Schedule IV.